Mein Warenkorb

PD-L2

PD-L2 Molekülinformation

Englischer NameProgrammed death-ligand 2Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-AliasPDCD1LG2,PDL2,Programmed death ligand 2,CD273,Butyrophilin B7-DC,PD-1 ligand 2,B7-DC,BA574F11.2,PDCD1L2,CD273 Antigen,B7DC,Btdc,B7 Dendritic Cell Molecule,PD-1-Ligand 2,PDCD1 ligand 2,Programmed cell death 1 ligand 2
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameProgrammed death-ligand 2
Target-AliasPDCD1LG2,PDL2,Programmed death ligand 2,CD273,Butyrophilin B7-DC,PD-1 ligand 2,B7-DC,BA574F11.2,PDCD1L2,CD273 Antigen,B7DC,Btdc,B7 Dendritic Cell Molecule,PD-1-Ligand 2,PDCD1 ligand 2,Programmed cell death 1 ligand 2
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

PD-L2 Molekülhintergrund

Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.

PD-L2 Molekülalias

PDL2,PD-L2,Butyrophilin B7-DC,CD273,PDCD1 ligand 2,PDCD1L2,PDCD1LG2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
CA-170CA-170; AUPM-170Phase 3 ClinicalAurigeneCarcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours
Details
IMGS-001IMGS-001Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterColorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
68Ga-Mirc415ClinicalBeijing Cancer HospitalLung Neoplasms
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns